Pfizer Inc. (NYSE:PFE) Receives $28.06 Average Target Price from Analysts

Pfizer Inc. (NYSE:PFE) has received a consensus rating of “Hold” from the nineteen research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, four have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $28.0588.

Several research firms have recently weighed in on PFE. Scotiabank assumed coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. HSBC reiterated a “buy” rating and issued a $29.00 price target on shares of Pfizer in a research note on Wednesday, December 10th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Longer-term growth narrative: commentary suggesting Pfizer is pursuing GLP‑1 and other high‑yield opportunities that could support future earnings and income-focused investor appeal. Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
• Neutral Sentiment: Market/price context: coverage noting PFE slid while broad markets rose — signals the move is driven by company-specific news rather than sector weakness; trading volume slightly below average. Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
• Negative Sentiment: Safety shock: Pfizer reported a patient death in a long‑term extension study involving Hympavzi (marstacimab). The company has opened a safety review and is reassessing related surgical protocols; the working theory reported by some outlets is a thrombotic event. This is the primary near‑term catalyst driving the stock lower due to potential trial, label or usage impacts and increased regulatory scrutiny. Pfizer says patient dies after receiving hemophilia drug in trial
• Negative Sentiment: Analyst reaction: coverage notes at least one downgrade to “Hold” tied to lower 2026 revenue guidance and uncertainty about growth trajectories — adds downward pressure by adjusting near‑term expectations and investor sentiment. Pfizer: Downgrade To ‘Hold’ On Lower 2026 Revenue Guidance And Potential Growth Tracks

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after acquiring an additional 10,198,330 shares during the period. State Street Corp boosted its position in Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Geode Capital Management LLC grew its stake in Pfizer by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after buying an additional 1,820,634 shares during the last quarter. Norges Bank acquired a new stake in Pfizer in the second quarter worth $2,270,157,000. Finally, Northern Trust Corp lifted its stake in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Pfizer stock opened at $24.89 on Friday. Pfizer has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The stock has a market cap of $141.49 billion, a P/E ratio of 14.47 and a beta of 0.46. The stock has a 50 day moving average of $25.12 and a 200-day moving average of $24.88.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts expect that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s payout ratio is presently 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.